Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CICC Expects Commercial Insurance Innovative Drug Catalog Adjustments to Help High-Value Innovative Drugs Land
Recommend 55 Positive 73 Negative 44 |
||||
|
||||
|
China's National Healthcare Security Administration (NHSA) has released the preliminary form review announcement for the adjustments of the basic medical insurance, maternity insurance, and work injury insurance drug catalogs, as well as the commercial insurance innovative drug catalog, according to CICC's research report. A total of 534 drugs have passed the preliminary form review. It is expected that the NHSA will initiate a dual catalog mechanism to provide a clear division of labor for medical insurance. The basic medical insurance catalog will cover essential clinical drugs, while the commercial insurance innovative catalog will focus on high-value drugs with important clinical value that are not covered by medical insurance. With the medical insurance as a foundation and the expansion of commercial insurance, CICC predicted that commercial insurance companies would be encouraged to provide stable long-term investment for innovative drug R&D through various channels such as innovative drug investment funds, which will be conducive to the landing of high-value innovative drugs with innovativeness and clinical value. CICC recommended investors pay attention to BEIGENE (06160.HK), SKB BIO-B (06990.HK), AKESO (09926.HK), INNOVENT BIO (01801.HK), ZAI LAB (09688.HK) (ZLAB.US), CSPC PHARMA (01093.HK), SINO BIOPHARM (01177.HK), 3SBIO (01530.HK), SIMCERE PHARMA (02096.HK), FOSUN PHARMA (02196.HK), GRAND PHARMA (00512.HK), and JW THERAP-B (02126.HK). AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
